Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
DNA Vaccines
Researchers from Vical, Inc. discuss findings in DNA vaccines
July 9th, 2008
A new study, 'Safety and immunogenicity of a bivalent cytomegalovirus DNA vaccine in healthy adult subjects,' is now available. "VCL-CB01, a candidate cytomegalovirus (CMV) DNA vaccine that contains plasmids encoding CMV phosphoprotein 65 (pp65) and glycoprotein B (gB) to induce cellular and humoral immune responses and that is formulated with poloxamer CRL1005 and benzalkonium chloride to enhance immune responses, was evaluated in a phase 1 clinical trial. VCL-CB01 was evaluated in 44 healthy adult subjects (22 CMV seronegative and 22 CMV seropositive) 18-43 years old," scientists in the United States report. "Thirty-two subjects received 1-or 5-mg doses of vaccine on...
Source: Vaccine Weekly (2008-07-09)
|
